Format

Send to:

Choose Destination
See comment in PubMed Commons below
Biol Chem. 2002 Jan;383(1):229-34.

Osteopontin modulates prostate carcinoma invasive capacity through RGD-dependent upregulation of plasminogen activators.

Author information

  • 1Department of Experimental Medicine, University of L'Aquila, Italy.

Abstract

Osteopontin, a non-collageneous bone matrix protein, is produced in several human tumors but its role in cancer progression has been only partially elucidated. In this study we investigated the potential role of osteopontin in the malignancy of prostate cancer cells. Chemotaxis and chemoinvasion analyses revealed a dose-dependent increase in PC3 cell movement induced by osteopontin and a strict dependence of cell invasion on alphavbeta3 integrin function. The pattern of protease expression was modified by osteopontin and was characterized by an upregulation of plasminogen activators. Our findings suggest that osteopontin may confer selective malignant potential to prostate cancer cells through the enhancement of their invasive and proteolytic capability.

PMID:
11928818
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for iFactory
    Loading ...
    Write to the Help Desk